Core Viewpoint - GenSight Biologics has received authorization from Israel's Ministry of Health for the early access treatment of its gene therapy candidate GS010/LUMEVOQ® for individual patients [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]

Core Viewpoint - GenSight Biologics has received compassionate use authorization from the French medicines safety agency ANSM for its innovative gene therapies targeting retinal neurodegenerative diseases and central nervous system disorders [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing gene therapies [1] - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1] Regulatory Update - The French medicines safety agency ANSM has granted compassionate use authorization (Autorisation d'Accès Compassionnel, or AA) for GenSight's therapies [1]

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and. ...

Core Insights - GenSight Biologics has received regulatory authorizations for its gene therapy GS010/LUMEVOQ® for Individual Patient Expanded Access in the United States [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]